SCHEMBL25367752

SCHEMBL25367752

CS(=O)(=O)Nc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(OC(F)(F)F)cc3)cs2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 3/20 0.55
▸ LMNA P02545 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ EPHX2 P34913 1/20 0.48
▸ NR1H4 Q96RI1 1/20 0.48
▸ KIF11 P52732 1/20 0.47
▸ IDH1 O75874 1/20 0.47
▸ TRPV1 Q8NER1 4/20 0.47
▸ MAPK1 P28482 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ DHX9 Q08211 1/20 0.44
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30544016 1.00 ABL1 (0.55) ABL1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL25368459 0.93 NPC1 (0.52) ABL1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL30543864 0.93 NPC1 (0.52) ABL1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL25368034 0.88 KMT2A (0.60) LMNASMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL25367472 0.86 MEN1 (0.53) RAB9ANR1H4IDH1MAPK1MEN1
SCHEMBL30543926 0.86 MEN1 (0.53) RAB9ANR1H4IDH1MAPK1MEN1
SCHEMBL25368128 0.86 EPHX2 (0.48) LMNASMN1; SMN2NPC1RAB9AEPHX2
SCHEMBL30543946 0.85 DHX9 (0.53) LMNASMN1; SMN2RAB9AMAPK1MEN1
SCHEMBL25368280 0.85 DHX9 (0.53) LMNASMN1; SMN2RAB9AMAPK1MEN1
SCHEMBL25368447 0.83 HPGD (0.51) LMNASMN1; SMN2NPC1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B ABL1 2926/4885LMNA 1392/4885SMN1; SMN2 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback